G. Lau

J. Chen, G. Lau, Chris L. P. Wong, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

HBeAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon

G. Lau, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East.

V. Cheng, G. Lau, C. Lo, 2003, Seminars in liver disease.

Three‐day lansoprazole quadruple therapy for Helicobacter pylori‐positive duodenal ulcers: a randomized controlled study

M. Yuen, G. Lau, W. Wong, 2001, Alimentary pharmacology & therapeutics.

Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

G. Lau, 2000, Journal of gastroenterology and hepatology.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Thomas Berg, Robert Flisiak, Philip McCloud, 2005, The New England journal of medicine.

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries

A. Dokmeci, S. Hamid, O. Yokosuka, 2015, Hepatology International.

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

M. Kumar, Chien-Jen Chen, Ding‐Shinn Chen, 2015, Hepatology International.

Enhanced Detection of Early Hepatocellular Carcinoma by Serum SELDI-TOF Proteomic Signature Combined with Alpha-Fetoprotein Marker

J. Luk, G. Lau, T. Poon, 2010, Annals of Surgical Oncology.

Hepatitis B infection in China.

G. Lau, 2001, Clinics in liver disease.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Y. Liaw, J. Kao, N. Leung, 2008, Hepatology international.

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

K. Chu, M. Yuen, Ching-lung Lai, 2002, The New England journal of medicine.

COVID-19: Discovery, diagnostics and drug development

T. Asselah, R. Schinazi, E. Pasmant, 2020, Journal of Hepatology.

Liver Intestine-Cadherin (CDH17) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma

J. Luk, X. Miao, Q. Cai, 2006, Clinical Cancer Research.

Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update *

Y. Liaw, N. Leung, G. Lau, 2003, Journal of gastroenterology and hepatology.

Colonoscopy Demand and Practice in a Regional Hospital over 9 Years in Hong Kong: Resource Implication for Cancer Screening

Wai Man Wong, M. Yuen, G. Lau, 2006, Digestion.

Clevudine for the treatment of chronic hepatitis B virus infection

G. Lau, C. Hui, 2005, Expert opinion on investigational drugs.

Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection

Y. Liaw, J. Kao, G. Lau, 2010, Digestive Diseases and Sciences.

1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B

P. Marcellin, C. Yurdaydın, G. Lau, 2003 .

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

A. Lok, G. Lau, D. Valla, 2003, Journal of hepatology.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.

Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.

G. Lau, S. Locarnini, A. Ayres, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B

P. Marcellin, B. Conway, G. Lau, 2004, Hepatology.

Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies

P. Marcellin, G. Lau, M. Peters, 2007, Hepatology international.

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation.

Y. Wen, D. Fong, W. Au, 2002, Blood.

Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients.

E. Wherry, Jiyuan Zhang, Zheng Zhang, 2009, Journal of hepatology.

Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B.

E. Wherry, Jiyuan Zhang, Zheng Zhang, 2008, Gastroenterology.

Title Asian-Pacific consensus statement on the management ofchronic hepatitis B : a 2008 update

Stephen, Y. Liaw, J. Kao, 2008 .

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti‐viral activity of clevudine for 12 weeks in patients with chronic hepatitis B

P. Marcellin, N. Leung, G. Lau, 2008, Alimentary pharmacology & therapeutics.

Peginterferon–α2a (40 kDa) (Pegasys®) for hepatitis B

G. Lau, C. Hui, 2005 .

95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

P. Marcellin, G. Lau, P. Farci, 2004 .

Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen–negative Chinese carriers

G. Lau, Jinjun Cheng, Jian Sun, 2001, Hepatology.

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

G. Lau, Y. Chao, T. Tanwandee, 2008, Hepatology international.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B

P. Marcellin, Y. Liaw, G. Lau, 2008, Hepatology.

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

P. Marcellin, C. Yurdaydın, G. Lau, 2009, Gastroenterology.

Response to antiviral treatment in patients infected with hepatitis B virus genotypes E–H

P. Marcellin, D. Häussinger, G. Lau, 2009, Journal of medical virology.

Treatment of hepatitis B e antigen-negative patients

G. Lau, C. Hui, 2007, Current treatment options in gastroenterology.

Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3)

Y. Liaw, J. Kao, N. Leung, 2008 .

103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP

P. Marcellin, C. Yurdaydın, G. Lau, 2008 .

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

P. Marcellin, C. Yurdaydın, G. Lau, 2006, Gut.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

E. Steyerberg, G. Lau, S. Zeuzem, 2009, Gastroenterology.

13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN)

M. Manns, P. Marcellin, G. Lau, 2010 .

683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY

P. Marcellin, C. Yurdaydın, G. Lau, 2008 .

50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B

P. Marcellin, G. Lau, E. Gane, 2006 .

49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

P. Marcellin, Y. Liaw, G. Lau, 2006 .

A new and sensitive method for the quantification of HBV cccDNA by real-time PCR.

G. Lau, H. Kung, Ying Chen, 2002, Biochemical and biophysical research communications.

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem.

G. Lau, R. Liang, Y. Kwong, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon for HBeAg-negative chronic hepatitis B: Teaching an old trick to an old dog?

W. Kim, P. Marcellin, G. Lau, 2005 .

A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection

P. Marcellin, B. Conway, G. Lau, 2003 .

Treatment of immunosuppressed chronic hepatitis B patients.

G. Lau, 2005, The Medical journal of Malaysia.

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study

N. Leung, G. Lau, 2010, The Korean journal of hepatology.

Immune system and hepatitis B virus infection.

Chee-Kin Hui, G. Lau, C. Hui, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Current treatments for patients with HBeAg‐positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion

G. Lau, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Current issues and future directions in treatment.

Chee-Kin Hui, G. Lau, C. Hui, 2006, Seminars in liver disease.

924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

P. Marcellin, C. Yurdaydın, G. Lau, 2009 .

treatment of chronic hepatitis

N. Leung, G. Lau, C. Hui, 2022 .

Immunological approaches to the breakdown of hepatitis B viral persistence.

G. Lau, W. Carman, B. Wang, 1998, Chinese Medical Journal.

Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation?

G. Lau, W. Lim, Cheuk-Kwong Lee, 1997, The Lancet.

Hepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation

G. Lau, C. Lo, See-Ching Chan, 2006 .

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.

Bing Li, Fan Li, Jing Chen, 2016, The lancet. Gastroenterology & hepatology.

Systemic inflammatory response syndrome in acute‐on‐chronic liver failure: Relevance of ‘golden window’: A prospective study

M. Kumar, Y. Chawla, M. Yuen, 2017, Journal of gastroenterology and hepatology.

Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study.

Fu-Sheng Wang, G. Lau, 2012, Journal of hepatology.

Loss of HBsAg in chronic hepatitis B carrier following high‐dose chemotherapy and autologous peripheral blood stem cell rescue for lymphoma

G. Lau, Cheuk-Kwong Lee, R. Liang, 1995, American journal of hematology.

917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B

P. Marcellin, G. Lau, M. Brunetto, 2009 .

HCV in hepatic failure: West and East do not meet

G. Lau, Roger Williams, 1999, Gut.

CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

P. Marcellin, C. Yurdaydın, G. Lau, 2009 .

A hepatitis B-free generation in China: from dream to reality.

G. Lau, J. Hou, R. Fan, 2016, The Lancet. Infectious diseases.

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Y. Chawla, R. Dhiman, M. Yuen, 2019, Hepatology International.

Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score

Jing Xu, Dong Ji, Dawei Zhang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma

Jiyuan Zhang, Zheng Zhang, Jun‐liang Fu, 2013, Hepatology.

One‐week ranitidine bismuth citrate‐based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance

M. Yuen, G. Lau, K. Lai, 2001, Alimentary pharmacology & therapeutics.

Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models

Y. Chawla, B. Sharma, S. Sarin, 2017, Hepatology International.

Shortening the duration of therapy for chronic hepatitis C infection.

T. O'Brien, G. Lau, S. Kottilil, 2017, The lancet. Gastroenterology & hepatology.

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

M. Kumar, J. Kao, B. Sharma, 2016, Hepatology International.

APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19

S. Sarin, A. Dokmeci, L. Lesmana, 2020, Hepatology International.

Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations

Y. Chawla, Justin C.Y. Wu, P. Angus, 2011, Hepatology international.

Detection of hepatitis C virus genome in formalin‐fixed paraffin‐embedded liver tissue by in situ reverse transcription polymerase chain reaction

G. Davis, G. Lau, J. Lau, 1994, Journal of medical virology.

Impact of metabolic risk factors on the severity and outcome of patients with alcohol‐associated acute‐on‐chronic liver failure

Y. Chawla, R. Dhiman, S. Sarin, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19

Jing Xu, G. Lau, Feng Wang, 2020, Metabolism.

Effect of COVID-19 on patients with compensated chronic liver diseases

Jing Xu, G. Lau, Peng Zhao, 2020, Hepatology International.

Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients.

Y. Chawla, R. Dhiman, M. Yuen, 2019, The American journal of gastroenterology.

The 10-year chronic liver disease spectrum evolution in China: experience from the largest tartiary special hospital with 21382 liver biopsy cases

G. Lau, Guo-feng Chen, D. Ji, 2018 .

Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus

G. Lau, Guo-feng Chen, D. Ji, 2015, Annals of Saudi medicine.

Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy.

G. Lau, R. Liang, A. Lie, 2002, Blood.

Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors.

Zheng Zhang, Fu-Sheng Wang, G. Lau, 2015, World journal of gastroenterology.

Reactivation of chronic hepatitis B infection

R. Liang, G. Lau, M. Beard, 2002 .

Reactivation of chronic hepatitis B viral infecion after bone marrow transplantation.

R. Liang, G. Lau, Fe Chen, 1996 .

Correction to: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Y. Chawla, R. Dhiman, M. Yuen, 2019, Hepatology International.

Management of chronic hepatitis B e antigen-negative disease: another step forward.

Fu-Sheng Wang, G. Lau, 2012, The Journal of infectious diseases.

Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data

J. Chen, G. Lau, Lungen Lu, 2016, PloS one.

Non‐alcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines

T. Saibara, G. Lau, G. Farrell, 2007, Journal of gastroenterology and hepatology.

Immunoglobulin M and A antibodies to hepatitis C core antigen in chronic hepatitis C virus infection

G. Davis, G. Lau, J. Lau, 1994, Journal of medical virology.

Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure

Y. Chawla, R. Dhiman, M. Rela, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF

R. Dhiman, S. Sarin, Z. Abbas, 2021, Hepatology International.

‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure

M. Kumar, M. Yuen, S. Sarin, 2021, Hepatology International.

Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats.

G. Lau, R. Poon, Y. Tong, 2009, Journal of ethnopharmacology.

Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs

G. Lau, H. Janssen, 2005, Hepatology.

Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis

G. Lau, Guo-feng Chen, D. Ji, 2017 .

Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B.

T. Asselah, P. Marcellin, Y. Liaw, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID‐19 Pandemic

J. Ward, G. Lau, 2020, Clinical liver disease.

Novel treatment for gastric intestinal metaplasia, a precursor to cancer

G. Lau, S. Lam, 2020, JGH open : an open access journal of gastroenterology and hepatology.

47th Annual meeting of the American Association for the Study of Liver Disease, November 1996

R. Liang, G. Lau, Fe Chen, 1997 .

Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’

Jing Xu, G. Lau, G. Cheng, 2020, Journal of Hepatology.

A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV

P. Marcellin, B. Conway, G. Lau, 2003 .

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant (BMT) recipients from anti-HBc+/anti-HBs+ BMT donors.

R. Liang, G. Lau, R. Williams, 1998 .